Request for Hysitron TI950 TriboIndenter Nanoindenter with Raman Spectroscopy

本建议书旨在购买Hysitron TI 950摩擦压痕仪/拉曼光谱仪 系统，这将增加纳米材料科学的能力（例如，纳米压痕， 纳米纤维）和高分辨率拉曼光谱能力（例如，化学 组合物、矿物/晶体同种型）与我们目前的仪器结合-提供了一种 显著提高了我们测量物理和化学性质的能力， 器官、组织、细胞、化合物、植入物和工程材料。实验室 对这种设备感兴趣的人参与了广泛的资助研究 计划，包括骨代谢，骨科，癌症生物学，糖尿病， 肥胖使用Hysitron TI 950系统，我们将能够测量真实材料 直接测量矿化和软组织的特性，而无需估计 基于宏观水平测试的参数，这些测试在纳米尺度上有缺陷。 此外，我们要求的特定仪器有能力收集 拉曼光谱和来自其的纳米压痕衍生的机械性质 微观，这将显着提高实验质量， 我们采取的测量，同时，将迎来大量的新线路， 我们目前还没有享受到的调查和合作。有许多 VA资助的印第安纳波利斯VA的调查人员将从以下方面受益匪浅 Hysitron TI 950系统的收购，包括Robling博士（骨质疏松症/机械， 转导），艾伦（骨质疏松症/抗再吸收剂），莫伊（慢性肾病）， Bellido（骨质疏松症/激素信号）、Roodman（多发性骨髓瘤）、Nakshatri （肌肉减少症/恶病质）、Chirgwin（骨髓瘤/骨细胞）和March（脂肪源性 干细胞）。此外，该系统将允许这些VA调查员中的每一个扩展 他们的研究计划，并开始发起新的合作与大型 印第安纳波利斯分校的生物医学工程社区，他们表示， 对系统有很大的兴趣。

This proposal is for the purchase of a Hysitron TI950 TriboIndenter/Raman Spectroscopy System, which will add nanoscale materials science capabilities (e.g., nanoindentation, nanofabrication) and high resolution Raman Spectroscopy capabilities (e.g., chemical composition, mineral/crystal isoforms) to our present instrumentation—providing a significant improvement in our ability to measure physical and chemical properties of organs, tissues, cells, compounds, implants, and engineered materials. The laboratories interested in this piece of equipment are involved in a wide range of funded research programs, including bone metabolism, orthopaedics, cancer biology, diabetes, and obesity. With the Hysitron TI950 system, we will be able to measure true material properties of mineralized and soft tissues directly, without the need to estimate parameters based on macro-level tests that have flawed translation to the nano-scale. In addition, the particular instrument we are requesting has the capability to collect Raman spectra and nanoindentation-derived mechanical properties from the same micro-moeity, which will significantly improve the quality of experiments and measurements that we take, and at the same time, will usher in a multitude of new lines of investigation and collaboration that we currently do not enjoy. There are numerous VA-funded investigators at the Indianapolis VA that would benefit greatly from acquisition of the Hysitron TI950 system, including Drs. Robling (osteoporosis/mechano- transduction), Allen (osteoporosis/anti-resorptives), Moe (chronic kidney disease), Bellido (osteoporosis/hormone signaling), Roodman (multiple myeloma), Nakshatri (sarcopenia/cachexia), Chirgwin (myeloma/osteocytes), and March (adipose-derived stem cells). Moreover, the system would allow each of these VA investigators to expand their research programs and begin initiating new collaborations with the large biomedical engineering community on the IU Indianapolis campus, who have expressed significant interest in the system.